Click here to get full coverage on Why IMNM stock could rally in 2025 - Quarterly Performance Summary & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Why IMNM stock could rally in 2025 - Quarterly Performance Summary & Free Expert Verified Stock Movement Alerts  nchmf.gov.vn

Why IMNM stock could rally in 2025 - Quarterly Performance Summary & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Click here to get full coverage on Why IMNM stock remains resilient - Treasury Yields & Real-Time Volume Triggers - newser.com

Why IMNM stock remains resilient - Treasury Yields & Real-Time Volume Triggers  newser.com

Why IMNM stock remains resilient - Treasury Yields & Real-Time Volume Triggers - newser.com

Click here to get full coverage on (IMNM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

(IMNM) Movement Within Algorithmic Entry Frameworks  news.stocktradersdaily.com

(IMNM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Click here to get full coverage on Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?  Yahoo Finance

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications - ScienceDirect.com

The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications  ScienceDirect.com

The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications - ScienceDirect.com

Click here to get full coverage on Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)  Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune - simplywall.st

Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune  simplywall.st

Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune - simplywall.st

Click here to get full coverage on $IMNM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 14% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?  Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Click here to get full coverage on IMNM: integrated multi-network model for identifying pepper leaf diseases - Frontiers

IMNM: integrated multi-network model for identifying pepper leaf diseases  Frontiers

IMNM: integrated multi-network model for identifying pepper leaf diseases - Frontiers

Click here to get full coverage on Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?  Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Click here to get full coverage on Is IMNM stock supported by strong fundamentals - Dividend Hike & Low Drawdown Trading Techniques - nchmf.gov.vn

Is IMNM stock supported by strong fundamentals - Dividend Hike & Low Drawdown Trading Techniques  nchmf.gov.vn

Is IMNM stock supported by strong fundamentals - Dividend Hike & Low Drawdown Trading Techniques - nchmf.gov.vn

Click here to get full coverage on Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy - ScienceDirect.com

Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy  ScienceDirect.com

Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy - ScienceDirect.com

Click here to get full coverage on Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha

Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM)  Seeking Alpha

Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Immunome (IMNM) Upgraded to Buy: Here's What You Should Know - Nasdaq

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know  Nasdaq

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know - Nasdaq

Click here to get full coverage on Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%  Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?  Yahoo Finance

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates  Yahoo Finance

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on Immunome Inc. (IMNM) reports earnings - qz.com

Immunome Inc. (IMNM) reports earnings  qz.com

Immunome Inc. (IMNM) reports earnings - qz.com

Click here to get full coverage on Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock - simplywall.st

Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock  simplywall.st

Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock - simplywall.st

Click here to get full coverage on Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R - GuruFocus

Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R  GuruFocus

Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R - GuruFocus

Click here to get full coverage on Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone  Stock Titan

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan

Click here to get full coverage on Goldman Sachs initiates coverage on Immunome stock with Buy rating - Investing.com

Goldman Sachs initiates coverage on Immunome stock with Buy rating  Investing.com

Goldman Sachs initiates coverage on Immunome stock with Buy rating - Investing.com

Click here to get full coverage on Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners - simplywall.st

Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners  simplywall.st

Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners - simplywall.st

Click here to get full coverage on Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’ - Stocktwits

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’  Stocktwits

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’ - Stocktwits

Click here to get full coverage on Immunome Secures Strategic Partnerships, Boosts Market Potential - StocksToTrade

Immunome Secures Strategic Partnerships, Boosts Market Potential  StocksToTrade

Immunome Secures Strategic Partnerships, Boosts Market Potential - StocksToTrade

Click here to get full coverage on Immunome Stock On the Rise Amid Strategic Collaborations - timothysykes.com

Immunome Stock On the Rise Amid Strategic Collaborations  timothysykes.com

Immunome Stock On the Rise Amid Strategic Collaborations - timothysykes.com

Click here to get full coverage on Immunome stock a ‘buy’ on ‘rich pipeline’ of oncology therapeutics: analysts - Proactive financial news

Immunome stock a ‘buy’ on ‘rich pipeline’ of oncology therapeutics: analysts  Proactive financial news

Immunome stock a ‘buy’ on ‘rich pipeline’ of oncology therapeutics: analysts - Proactive financial news

Click here to get full coverage on Dysphagia During Pharyngeal and Esophageal Phase of Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report - Cureus

Dysphagia During Pharyngeal and Esophageal Phase of Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report  Cureus

Dysphagia During Pharyngeal and Esophageal Phase of Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report - Cureus

Click here to get full coverage on Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha

Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM)  Seeking Alpha

Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on 3 Small-Cap Stocks With Big Growth Potential - MarketBeat

3 Small-Cap Stocks With Big Growth Potential  MarketBeat

3 Small-Cap Stocks With Big Growth Potential - MarketBeat

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - sharewise.com

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates  sharewise.com

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - sharewise.com

Click here to get full coverage on Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update  BioSpace

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace

Click here to get full coverage on Immunome CEO Clay Siegall buys $999k in stock - Investing.com

Immunome CEO Clay Siegall buys $999k in stock  Investing.com

Immunome CEO Clay Siegall buys $999k in stock - Investing.com

Click here to get full coverage on Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target - timothysykes.com

Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target  timothysykes.com

Goldman Sachs Sees Positive Outlook for Immunome with $26 Price Target - timothysykes.com

Click here to get full coverage on Infinimmune Announces Research Collaboration with Immunome - Business Wire

Infinimmune Announces Research Collaboration with Immunome  Business Wire

Infinimmune Announces Research Collaboration with Immunome - Business Wire

Click here to get full coverage on What analysts say about IMNM stock - Support Level Holds & High Profit Market Ideas - earlytimes.in

What analysts say about IMNM stock - Support Level Holds & High Profit Market Ideas  earlytimes.in

What analysts say about IMNM stock - Support Level Holds & High Profit Market Ideas - earlytimes.in

Click here to get full coverage on Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43  Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire

Click here to get full coverage on Immunome Advances Cancer Therapy Pipeline Amid Financial Loss - TipRanks

Immunome Advances Cancer Therapy Pipeline Amid Financial Loss  TipRanks

Immunome Advances Cancer Therapy Pipeline Amid Financial Loss - TipRanks

Click here to get full coverage on Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update  Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC  Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire

Click here to get full coverage on Immunome earnings beat by $0.12, revenue topped estimates - Investing.com

Immunome earnings beat by $0.12, revenue topped estimates  Investing.com

Immunome earnings beat by $0.12, revenue topped estimates - Investing.com

Click here to get full coverage on argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewswire

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies  GlobeNewswire

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewswire

Click here to get full coverage on Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs - Nasdaq

Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs  Nasdaq

Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs - Nasdaq

Click here to get full coverage on Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort - BMC Musculoskeletal Disorders

Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort  BMC Musculoskeletal Disorders

Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort - BMC Musculoskeletal Disorders

Click here to get full coverage on Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis - ScienceDirect.com

Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis  ScienceDirect.com

Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis - ScienceDirect.com

Click here to get full coverage on Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies - BMC Pulmonary Medicine

Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies  BMC Pulmonary Medicine

Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies - BMC Pulmonary Medicine

Click here to get full coverage on Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM) - Seeking Alpha

Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM)  Seeking Alpha

Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Biotech's Target Price 183.757% Higher Than Current - streetwisereports.com

Biotech's Target Price 183.757% Higher Than Current  streetwisereports.com

Biotech's Target Price 183.757% Higher Than Current - streetwisereports.com

Click here to get full coverage on The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China - Frontiers

The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China  Frontiers

The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China - Frontiers

Click here to get full coverage on Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy - ScienceDirect.com

Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy  ScienceDirect.com

Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy - ScienceDirect.com

Click here to get full coverage on Immunome: Enthusiasm For New Management Has Faded (NASDAQ:IMNM) - Seeking Alpha

Immunome: Enthusiasm For New Management Has Faded (NASDAQ:IMNM)  Seeking Alpha

Immunome: Enthusiasm For New Management Has Faded (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares - Yahoo Finance

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares  Yahoo Finance

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares - Yahoo Finance

Click here to get full coverage on IVIg Shows 85% Response Rate in IMNM Patients - Physician's Weekly

IVIg Shows 85% Response Rate in IMNM Patients  Physician's Weekly

IVIg Shows 85% Response Rate in IMNM Patients - Physician's Weekly

Click here to get full coverage on Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features - BMC Musculoskeletal Disorders

Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features  BMC Musculoskeletal Disorders

Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features - BMC Musculoskeletal Disorders

Click here to get full coverage on Dermatomyositis, polymyositis and immune-mediated necrotising myopathies - ScienceDirect.com

Dermatomyositis, polymyositis and immune-mediated necrotising myopathies  ScienceDirect.com

Dermatomyositis, polymyositis and immune-mediated necrotising myopathies - ScienceDirect.com

Click here to get full coverage on Brain Pathology | ISN Neuropathology Journal - Wiley Online Library

Brain Pathology | ISN Neuropathology Journal  Wiley Online Library

Brain Pathology | ISN Neuropathology Journal - Wiley Online Library

Click here to get full coverage on IMNM IPO News - Preclinical oncology biotech Immunome sets terms for $30 million IPO - renaissancecapital.com

IMNM IPO News - Preclinical oncology biotech Immunome sets terms for $30 million IPO  renaissancecapital.com

IMNM IPO News - Preclinical oncology biotech Immunome sets terms for $30 million IPO - renaissancecapital.com

Click here to get full coverage on IMNM IPO News - Preclinical oncology biotech Immunome files for a $30 million IPO - renaissancecapital.com

IMNM IPO News - Preclinical oncology biotech Immunome files for a $30 million IPO  renaissancecapital.com

IMNM IPO News - Preclinical oncology biotech Immunome files for a $30 million IPO - renaissancecapital.com

Click here to get full coverage on Muscle Involvement Seen in Dermatomyositis With and Without Anti-Mi2 Autoantibodies - Neurology Advisor

Muscle Involvement Seen in Dermatomyositis With and Without Anti-Mi2 Autoantibodies  Neurology Advisor

Muscle Involvement Seen in Dermatomyositis With and Without Anti-Mi2 Autoantibodies - Neurology Advisor

Click here to get full coverage on Immunome Announces Completion of Purchase of Assets from Atreca - Business Wire

Immunome Announces Completion of Purchase of Assets from Atreca  Business Wire

Immunome Announces Completion of Purchase of Assets from Atreca - Business Wire

Click here to get full coverage on Immunome Appoints Roee Shahar as Executive Vice President, Commercial - BioSpace

Immunome Appoints Roee Shahar as Executive Vice President, Commercial  BioSpace

Immunome Appoints Roee Shahar as Executive Vice President, Commercial - BioSpace

Click here to get full coverage on Immunome leaps on news of Phase III asset buy - The Pharma Letter

Immunome leaps on news of Phase III asset buy  The Pharma Letter

Immunome leaps on news of Phase III asset buy - The Pharma Letter

Click here to get full coverage on Immunome Reports Third Quarter 2022 Financial Results - FinancialContent

Immunome Reports Third Quarter 2022 Financial Results  FinancialContent

Immunome Reports Third Quarter 2022 Financial Results - FinancialContent

Click here to get full coverage on Immunome Reports First Quarter 2022 Financial Results - FinancialContent

Immunome Reports First Quarter 2022 Financial Results  FinancialContent

IMNM

Price Chart

Key Statistics

Technicals

About IMNM

Latest News

Why IMNM stock could rally in 2025 - Quarterly Performance Summary & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Why IMNM stock remains resilient - Treasury Yields & Real-Time Volume Triggers - newser.com

(IMNM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Advanced Charts

Top Gainers

Top Losers